Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Melphalan; Prednisone; Vincristine
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms LYMA; LyMa-MRD

15 Jun 2023 Results assessing Long-Term Follow-Up of Rituximab Maintenance in Young Patients with Mantle Cell Lymphoma presented at the 28th Congress of the European Haematology Association
17 Jun 2021 Results evaluating high-risk mantle cell lymphoma patients, presented at the 26th Congress of the European Haematology Association
08 Dec 2020 Results of minimal residual disease (n=195) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com